MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer-Reference-Cited by-同舟云学术

MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer

Published:2023-04 Issue: Volume:559 Page:216116
ISSN:0304-3835
Container-title:Cancer Letters
language:en
Short-container-title:Cancer Letters

Author:

Morimoto Yoshihiro,Yamashita Nami,Hirose Haruka,Fushimi Atsushi,Haratake Naoki,Daimon Tatsuaki,Bhattacharya Atrayee,Ahmad Rehan,Suzuki Yozo,Takahashi Hidekazu,Kufe Donald W.^ORCID

Funder

Baton Rouge Area Foundation

Dana Farber Cancer Institute

Solid Wood Innovation

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

National Institutes of Health

China Scholarship Council

National Cancer Institute

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference63 articles.

1. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies;Clarke;J. Gastrointest. Oncol.,2015

2. Precision oncology in metastatic colorectal cancer - from biology to medicine;Di Nicolantonio;Nat. Rev. Clin. Oncol.,2021

3. Current therapeutic strategies in BRAF-mutant metastatic colorectal cancer;Grassi;Front. Oncol.,2021

4. BRAF-mutated colorectal cancer exhibits distinct clinicopathological features from wild-type BRAF-expressing cancer independent of the microsatellite instability status;Jang;J. Kor. Med. Sci.,2017

5. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis;Ogino;Mod. Pathol.,2006

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Strategies for enhancing non-small cell lung cancer treatment: Integrating Chinese herbal medicines with epidermal growth factor receptor-tyrosine kinase inhibitors therapy;European Journal of Pharmacology;2024-10

2. PDP1 promotes KRAS mutant colorectal cancer progression by serving as a scaffold for BRAF and MEK1;Cancer Letters;2024-08

3. A comprehensive overview of the molecular features and therapeutic targets in BRAF^V600E‐mutant colorectal cancer;Clinical and Translational Medicine;2024-07

4. Molecular Landscape and Therapeutic Strategies against Colorectal Cancer;Cancers;2024-04-18

5. MUC1 and MUC16: critical for immune modulation in cancer therapeutics;Frontiers in Immunology;2024-02-01